E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Acute Coronary Syndromes in the GUSTO-IIb Trial Prognostic Insights and Impact of Recurrent Ischemia
Paul W. Armstrong,Yuling Fu,Wei-Ching Chang,Eric J. Topol,Christopher B. Granger,Amadeo Betriu,Frans Van de Werf,Kerry L. Lee,Robert M. Califf +8 more
TL;DR: In this paper, the 1-year prognosis of the 12 142 patients enrolled in the GUSTO-IIb trial by the presence or absence of ST-segment elevation was assessed and the incidence of recurrent ischemia and its impact on outcomes.
Journal ArticleDOI
Comparisons of Characteristics and Outcomes Among Women and Men With Acute Myocardial Infarction Treated With Thrombolytic Therapy
W. Douglas Weaver,Harvey D. White,Robert G. Wilcox,Philip E. Aylward,Douglas C. Morris,Alan D. Guerci,E. Magnus Ohman,Gabriel I. Barbash,Amadeo Betriu,Zygmunt Sadowski,Eric J. Topol,Robert M. Califf +11 more
TL;DR: Women who received thrombolytic therapy for treatment of acute myocardial infarction were at greater risk for both fatal and nonfatal complications than men.
Journal ArticleDOI
Outmigration For Coronary Bypass Surgery in an Era of Public Dissemination of Clinical Outcomes
Nowamagbe A. Omoigui,Dave P. Miller,Kimberly Brown,Kingsley Annan,Delos Cosgrove,Bruce H. Lytle,Floyd Loop,Eric J. Topol +7 more
TL;DR: Public dissemination of outcome data may have been associated with increased referral of high-risk patients from New York to an out-of-state regional medical center.
Journal ArticleDOI
Individualized Medicine from Prewomb to Tomb
TL;DR: Well beyond the allure of the matchless fingerprint or snowflake concept, these singular, individual data and information set up a remarkable and unprecedented opportunity to improve medical treatment and develop preventive strategies to preserve health.
Journal Article
Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial
Eric J. Topol,Robert M. Califf,R. J. Simes,F. Van de Werf,Rafael Diaz,E. Paoloasso,PE Aylward,Anthony C Keech,Werner Klein,Leopoldo S Piegas,I. Tomov,Paul W. Armstrong,Petr Widimsky,Peer Grande,M. Halinen,A Vahanian,Karl-Ludwig Neuhaus,A.P. Dimas,Harvey D. White,I. Preda,A Kristinsson,Diego Ardissino,D. Tzivoni,S. Madsen,D. Sugrue,Zygmunt Sadowski,Ricardo Seabra-Gomes,E. Apetrei,Anthony J. Dalby,Amadeo Betriu,M. Pfisterer,F.W. Verheugt,Keith A.A. Fox,Eric R. Bates,W.B. Gibler,Christopher B. Granger,Robert A. Harrington,Judith S. Hochman,David R. Holmes,Neal S. Kleiman,Kerry L. Lee,D.J. Molietrno,L K Newby,Erik Magnus Ohman +43 more
TL;DR: Sibrafiban showed no additional benefit over aspirin for secondary prevention of major ischaemic events after an acute coronary syndrome, and was associated with more dose-related bleeding.